세계의 합성 호르몬 시장 - 시장 규모, 점유율, 동향, 기회, 예측, 제품별, 투여 경로별, 용도별, 최종 사용자별, 지역별, 경쟁별(2020-2030년)
Synthetic Hormones Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product, By Route of Administration, By Application, By End User, By Region, and Competition, 2020-2030F
합성 호르몬 세계 시장은 2024년에는 5억 9,565만 달러로 평가되었고, 2030년까지의 CAGR은 12.15%를 나타낼 전망이며, 예측 기간 중에 강력한 성장이 전망되고 있습니다.
합성 호르몬은 인체에 자연적으로 존재하는 호르몬을 실험실에서 제조한 것입니다. 이 호르몬은 내분비선에서 생산되는 호르몬의 화학 구조와 기능을 모방하지만 체내가 아닌 외부에서 생산됩니다. 합성 호르몬은 호르몬 대체 요법(HRT), 피임, 호르몬 관련 질환의 치료 등 다양한 의료 목적으로 사용됩니다. 호르몬 균형의 혼란에 대처하고, 호르몬 관련 질병의 증상을 관리하고, 피임을 수행하기 위해 건강 관리 종사자가 처방됩니다. 합성 호르몬은 일반적으로 폐경기, 갑상선 기능 저하증, 호르몬 관련 암, 불임 치료 등의 치료에 사용됩니다. 이 호르몬은 피임 알약, 패치, 주사, 자궁 내 피임기구(IUD)와 같은 피임법에도 필수적입니다. 이 호르몬은 배란을 억제하고 자궁 경관 점액을 진하게하고 자궁 내막을 변화시켜 수정란의 착상을 방지함으로써 기능합니다.
| 시장 개요 |
| 예측 기간 |
2026-2030년 |
| 시장 규모 : 2024년 |
5억 9,565만 달러 |
| 시장 규모 : 2030년 |
11억 8,778만 달러 |
| CAGR : 2025-2030년 |
12.15% |
| 급성장 부문 |
스테로이드 호르몬 |
| 최대 시장 |
북미 |
선진국을 중심으로 한 세계적인 고령화가 합성 호르몬 요법 수요에 계속 기여하고 있습니다.
주요 시장 성장 촉진요인
호르몬 관련 질환의 유병률 증가
주요 시장 과제
바이오 아이덴티컬 호르몬과의 경쟁
바이오 아이덴티컬 호르몬의 보험 적용은 합성 호르몬에 비해 일반적이지 않기 때문에 환자의 자기 부담액이 높아질 수 있습니다.
주요 시장 동향
맞춤형 의료에 주목
목차
제1장 개요
제2장 조사 방법
제3장 주요 요약
제4장 고객의 목소리
제5장 세계의 합성 호르몬 시장 전망
- 시장 규모와 예측
- 시장 점유율·예측
- 제품별(아미노산 유도체, 펩티드 호르몬, 스테로이드 호르몬)
- 투여 경로별(정맥내, 비강, 경구, 좌약, 국소)
- 용도별(성장 호르몬 결핍증, 남성성선 기능 저하증, 갱년기 장애, 갑상선 호르몬 결핍증)
- 최종 사용자별(병원 약국, 온라인 약국, 소매 약국)
- 지역별
- 기업별(2024년)
- 시장 맵
제6장 북미의 합성 호르몬 시장 전망
- 시장 규모와 예측
- 시장 점유율 및 예측
- 북미 : 국가별 분석
제7장 유럽의 합성 호르몬 시장 전망
- 시장 규모와 예측
- 시장 점유율 및 예측
- 유럽 : 국가별 분석
제8장 아시아태평양의 합성 호르몬 시장 전망
- 시장 규모와 예측
- 시장 점유율 및 예측
- 아시아태평양 : 국가별 분석
제9장 남미의 합성 호르몬 시장 전망
- 시장 규모와 예측
- 시장 점유율 및 예측
- 남미 : 국가별 분석
제10장 중동 및 아프리카의 합성 호르몬 시장 전망
- 시장 규모와 예측
- 시장 점유율 및 예측
- 중동 및 아프리카 : 국가별 분석
제11장 시장 역학
제12장 시장 동향과 발전
제13장 세계의 합성 호르몬 시장 : SWOT 분석
제14장 경쟁 구도
- Acerus Pharmaceuticals Corp.
- American Regent, Inc.
- Anhui Anke Biotechnology(Group) Co. Ltd.
- BioPartners, Inc
- Eli Lilly and Company
- Endo Pharmaceuticals, Inc.
- F. Hoffmann-La Roche Ltd.
- IBSA Institut Biochimique SA
- Lupin Pharmaceuticals, Inc.
- Pfizer, Inc
제15장 전략적 제안
제16장 기업 소개와 면책사항
SHW
The Global Synthetic Hormones Market was valued at USD 595.65 million in 2024 and is expected to experience robust growth during the forecast period, with a projected CAGR of 12.15% through 2030. Synthetic hormones are laboratory-manufactured versions of naturally occurring hormones in the human body. These hormones mimic the chemical structure and functions of those produced by the endocrine glands but are produced externally rather than within the body. Synthetic hormones serve various medical purposes, including hormone replacement therapy (HRT), contraception, and the treatment of hormone-related conditions. They are prescribed by healthcare providers to address hormonal imbalances, manage symptoms of hormone-related disorders, and provide contraception. Synthetic hormones are commonly used in the treatment of conditions such as menopause symptoms, hypothyroidism, hormone-related cancers, and fertility control. These hormones are also integral to contraceptive methods such as birth control pills, patches, injections, and intrauterine devices (IUDs). They function by inhibiting ovulation, thickening cervical mucus, and altering the uterine lining to prevent the implantation of a fertilized egg.
| Market Overview |
|---|
| Forecast Period | 2026-2030 |
| Market Size 2024 | USD 595.65 Million |
| Market Size 2030 | USD 1187.78 Million |
| CAGR 2025-2030 | 12.15% |
| Fastest Growing Segment | Steroid Hormones |
| Largest Market | North America |
The aging global population, especially in developed countries, continues to contribute to the demand for synthetic hormone therapies.
Key Market Drivers
Increasing Prevalence of Hormonal Disorders
The growing incidence of hormonal disorders is a major driver for the expansion of the global synthetic hormones market. Hormonal imbalances can affect various physiological functions, leading to chronic diseases, reproductive health issues, metabolic disorders, and growth abnormalities. Approximately 60 to 80 million couples globally face infertility challenges, driving the demand for hormone-based treatments and assisted reproductive technologies. In addition, developing nations often experience significant gaps in access to contraception, creating new opportunities for expanded family planning solutions. The lack of safe reproductive healthcare results in 115,000 to 204,000 deaths annually due to unsafe abortion practices, underscoring the urgent need for enhanced healthcare infrastructure and investment in reproductive health services.
As the number of patients diagnosed with hormonal disorders rises, the demand for synthetic hormone therapies has increased. Conditions such as hypothyroidism, adrenal insufficiency, and menopause-related complications require long-term hormone replacement therapy (HRT). Synthetic hormones such as levothyroxine (for thyroid disorders), estrogen and progesterone (for menopause), and corticosteroids (for adrenal gland deficiencies) are essential in managing these conditions. The global population of postmenopausal women is expanding, with women aged 50 and older comprising 26% of the global female population in 2021, up from 22% a decade earlier. This demographic shift, coupled with increasing life expectancy, has led to greater demand for HRT, menopause management, and age-related healthcare innovations.
Diabetes, especially Type 1 diabetes, is another major hormonal disorder, impacting over 425 million people worldwide. With an expected increase in diabetes cases, the demand for synthetic insulin therapies is growing, which is a key segment within the synthetic hormones market. Pharmaceutical companies are investing in advanced insulin formulations and delivery systems, such as long-acting insulin analogs and smart insulin pens, to meet the demand for these therapies. Additionally, infertility due to lifestyle changes, stress, delayed pregnancies, and environmental factors has increased the need for assisted reproductive technologies (ART). Synthetic hormones such as gonadotropins, progesterone, and estrogen are essential in ART procedures like in-vitro fertilization (IVF) and ovulation induction therapies.
Key Market Challenges
Competition from Bioidentical Hormones
Bioidentical hormones, often perceived as more "natural" and less likely to cause adverse effects, present a growing competition to traditional synthetic hormones. Some consumers and healthcare providers prefer bioidentical hormones due to their customization and perceived safety benefits. Bioidentical hormones are often marketed aggressively, highlighting their advantages over synthetic hormones. Additionally, bioidentical hormones may be compounded individually by pharmacies to meet patients' specific needs, further increasing their appeal.
However, bioidentical hormones face different regulatory scrutiny than synthetic hormones and are sometimes classified as dietary supplements rather than pharmaceuticals, potentially leading to variations in quality and safety standards. Despite the ongoing debate about their safety and efficacy, bioidentical hormones may lack the extensive clinical data supporting synthetic hormones. Moreover, their compounded nature can result in variations in formulation and dosage, complicating the establishment of consistent treatment protocols.
Insurance coverage for bioidentical hormones is often less common than for synthetic hormones, which can result in higher out-of-pocket costs for patients.
Key Market Trends
Focus on Personalized Medicine
A key trend in the Global Synthetic Hormones Market is the growing emphasis on personalized medicine. Personalized medicine enables healthcare providers to tailor hormone therapy and dosages based on individual patients' hormonal imbalances, genetics, and responses to treatment. This approach aims to deliver more effective and efficient treatment outcomes, reducing adverse reactions and improving patient safety and compliance. By considering individual factors such as genetic predisposition and response to treatment, personalized medicine helps minimize unnecessary interventions and optimize hormone therapy.
In the treatment of conditions such as menopause or hypogonadism, personalized medicine allows for customized hormone replacement therapy (HRT) that targets the unique needs of each patient, ensuring better symptom relief and hormonal balance. Genetic testing can identify individuals at higher risk for hormone-related disorders or cancers, allowing for early intervention and prevention. Continuous patient monitoring allows for real-time adjustments to treatment plans, improving therapeutic outcomes. Additionally, personalized medicine can guide treatment decisions for hormone-related cancers, such as breast and prostate cancer, by identifying patients most likely to benefit from specific synthetic hormone therapies.
Key Market Players
- Acerus Pharmaceuticals Corp.
- American Regent, Inc.
- Anhui Anke Biotechnology (Group) Co. Ltd.
- BioPartners, Inc.
- Eli Lilly and Company
- Endo Pharmaceuticals, Inc.
- F. Hoffmann-La Roche Ltd.
- IBSA Institut Biochimique SA
- Lupin Pharmaceuticals, Inc.
- Pfizer, Inc.
Report Scope
This report segments the Global Synthetic Hormones Market into the following categories, in addition to detailing the industry trends:
Synthetic Hormones Market, by Product:
- Amino Acid Derivatives
- Peptide Hormones
- Steroid Hormones
Synthetic Hormones Market, by Route of Administration:
- Intravenous
- Nasal
- Oral
- Suppository
- Topical
Synthetic Hormones Market, by Application:
- Growth Hormone Deficiency
- Male Hypogonadism
- Menopause
- Thyroid Hormone Deficiency
Synthetic Hormones Market, by End-User:
- Hospital Pharmacies
- Online Pharmacies
- Retail Pharmacies
Synthetic Hormones Market, by Region:
- North America (United States, Canada, Mexico)
- Asia-Pacific (China, India, South Korea, Australia, Japan)
- Europe (Germany, France, United Kingdom, Spain, Italy)
- South America (Brazil, Argentina, Colombia)
- Middle East & Africa (South Africa, Saudi Arabia, UAE)
Competitive Landscape
The report provides detailed company profiles of the major players in the Global Synthetic Hormones Market.
Available Customizations:
This Global Synthetic Hormones Market report offers customizations to meet specific company needs. The following options are available:
- Company Information: Detailed analysis and profiling of additional market players (up to five).
Table of Contents
1. Product Overview
- 1.1. Market Definition
- 1.2. Scope of the Market
- 1.2.1. Markets Covered
- 1.2.2. Years Considered for Study
- 1.2.3. Key Market Segmentations
2. Research Methodology
- 2.1. Objective of the Study
- 2.2. Baseline Methodology
- 2.3. Key Industry Partners
- 2.4. Major Association and Secondary Sources
- 2.5. Forecasting Methodology
- 2.6. Data Triangulation & Validation
- 2.7. Assumptions and Limitations
3. Executive Summary
- 3.1. Overview of the Market
- 3.2. Overview of Key Market Segmentations
- 3.3. Overview of Key Market Players
- 3.4. Overview of Key Regions/Countries
- 3.5. Overview of Market Drivers, Challenges, Trends
4. Voice of Customer
5. Synthetic Hormones Market Outlook
- 5.1. Market Size & Forecast
- 5.2. Market Share & Forecast
- 5.2.1. By Product (Amino Acid Derivatives, Peptide Hormone, Steroid Hormones)
- 5.2.2. By Route of Administration (Intravenous, Nasal, Oral, Suppository, Topical)
- 5.2.3. By Application (Growth Hormone Deficiency, Male Hypogonadism, Menopause, Thyroid Hormone Deficiency)
- 5.2.4. By End User (Hospital Pharmacies, Online Pharmacies, Retail Pharmacies)
- 5.2.5. By Region
- 5.2.6. By Company (2024)
- 5.3. Market Map
6. North America Synthetic Hormones Market Outlook
- 6.1. Market Size & Forecast
- 6.2. Market Share & Forecast
- 6.2.1. By Product
- 6.2.2. By Route of Administration
- 6.2.3. By Application
- 6.2.4. By End User
- 6.2.5. By Country
- 6.3. North America: Country Analysis
- 6.3.1. United States Synthetic Hormones Market Outlook
- 6.3.1.1. Market Size & Forecast
- 6.3.1.2. Market Share & Forecast
- 6.3.1.2.1. By Product
- 6.3.1.2.2. By Route of Administration
- 6.3.1.2.3. By Application
- 6.3.1.2.4. By End User
- 6.3.2. Canada Synthetic Hormones Market Outlook
- 6.3.2.1. Market Size & Forecast
- 6.3.2.2. Market Share & Forecast
- 6.3.2.2.1. By Product
- 6.3.2.2.2. By Route of Administration
- 6.3.2.2.3. By Application
- 6.3.2.2.4. By End User
- 6.3.3. Mexico Synthetic Hormones Market Outlook
- 6.3.3.1. Market Size & Forecast
- 6.3.3.2. Market Share & Forecast
- 6.3.3.2.1. By Product
- 6.3.3.2.2. By Route of Administration
- 6.3.3.2.3. By Application
- 6.3.3.2.4. By End User
7. Europe Synthetic Hormones Market Outlook
- 7.1. Market Size & Forecast
- 7.2. Market Share & Forecast
- 7.2.1. By Product
- 7.2.2. By Route of Administration
- 7.2.3. By Application
- 7.2.4. By End User
- 7.2.5. By Country
- 7.3. Europe: Country Analysis
- 7.3.1. Germany Synthetic Hormones Market Outlook
- 7.3.1.1. Market Size & Forecast
- 7.3.1.2. Market Share & Forecast
- 7.3.1.2.1. By Product
- 7.3.1.2.2. By Route of Administration
- 7.3.1.2.3. By Application
- 7.3.1.2.4. By End User
- 7.3.2. United Kingdom Synthetic Hormones Market Outlook
- 7.3.2.1. Market Size & Forecast
- 7.3.2.2. Market Share & Forecast
- 7.3.2.2.1. By Product
- 7.3.2.2.2. By Route of Administration
- 7.3.2.2.3. By Application
- 7.3.2.2.4. By End User
- 7.3.3. Italy Synthetic Hormones Market Outlook
- 7.3.3.1. Market Size & Forecast
- 7.3.3.2. Market Share & Forecast
- 7.3.3.2.1. By Product
- 7.3.3.2.2. By Route of Administration
- 7.3.3.2.3. By Application
- 7.3.3.2.4. By End User
- 7.3.4. France Synthetic Hormones Market Outlook
- 7.3.4.1. Market Size & Forecast
- 7.3.4.2. Market Share & Forecast
- 7.3.4.2.1. By Product
- 7.3.4.2.2. By Route of Administration
- 7.3.4.2.3. By Application
- 7.3.4.2.4. By End User
- 7.3.5. Spain Synthetic Hormones Market Outlook
- 7.3.5.1. Market Size & Forecast
- 7.3.5.2. Market Share & Forecast
- 7.3.5.2.1. By Product
- 7.3.5.2.2. By Route of Administration
- 7.3.5.2.3. By Application
- 7.3.5.2.4. By End User
8. Asia-Pacific Synthetic Hormones Market Outlook
- 8.1. Market Size & Forecast
- 8.2. Market Share & Forecast
- 8.2.1. By Product
- 8.2.2. By Route of Administration
- 8.2.3. By Application
- 8.2.4. By End User
- 8.2.5. By Country
- 8.3. Asia-Pacific: Country Analysis
- 8.3.1. China Synthetic Hormones Market Outlook
- 8.3.1.1. Market Size & Forecast
- 8.3.1.2. Market Share & Forecast
- 8.3.1.2.1. By Product
- 8.3.1.2.2. By Route of Administration
- 8.3.1.2.3. By Application
- 8.3.1.2.4. By End User
- 8.3.2. India Synthetic Hormones Market Outlook
- 8.3.2.1. Market Size & Forecast
- 8.3.2.2. Market Share & Forecast
- 8.3.2.2.1. By Product
- 8.3.2.2.2. By Route of Administration
- 8.3.2.2.3. By Application
- 8.3.2.2.4. By End User
- 8.3.3. Japan Synthetic Hormones Market Outlook
- 8.3.3.1. Market Size & Forecast
- 8.3.3.2. Market Share & Forecast
- 8.3.3.2.1. By Product
- 8.3.3.2.2. By Route of Administration
- 8.3.3.2.3. By Application
- 8.3.3.2.4. By End User
- 8.3.4. South Korea Synthetic Hormones Market Outlook
- 8.3.4.1. Market Size & Forecast
- 8.3.4.2. Market Share & Forecast
- 8.3.4.2.1. By Product
- 8.3.4.2.2. By Route of Administration
- 8.3.4.2.3. By Application
- 8.3.4.2.4. By End User
- 8.3.5. Australia Synthetic Hormones Market Outlook
- 8.3.5.1. Market Size & Forecast
- 8.3.5.2. Market Share & Forecast
- 8.3.5.2.1. By Product
- 8.3.5.2.2. By Route of Administration
- 8.3.5.2.3. By Application
- 8.3.5.2.4. By End User
9. South America Synthetic Hormones Market Outlook
- 9.1. Market Size & Forecast
- 9.2. Market Share & Forecast
- 9.2.1. By Product
- 9.2.2. By Route of Administration
- 9.2.3. By Application
- 9.2.4. By End User
- 9.2.5. By Country
- 9.3. South America: Country Analysis
- 9.3.1. Brazil Synthetic Hormones Market Outlook
- 9.3.1.1. Market Size & Forecast
- 9.3.1.2. Market Share & Forecast
- 9.3.1.2.1. By Product
- 9.3.1.2.2. By Route of Administration
- 9.3.1.2.3. By Application
- 9.3.1.2.4. By End User
- 9.3.2. Argentina Synthetic Hormones Market Outlook
- 9.3.2.1. Market Size & Forecast
- 9.3.2.2. Market Share & Forecast
- 9.3.2.2.1. By Product
- 9.3.2.2.2. By Route of Administration
- 9.3.2.2.3. By Application
- 9.3.2.2.4. By End User
- 9.3.3. Colombia Synthetic Hormones Market Outlook
- 9.3.3.1. Market Size & Forecast
- 9.3.3.2. Market Share & Forecast
- 9.3.3.2.1. By Product
- 9.3.3.2.2. By Route of Administration
- 9.3.3.2.3. By Application
- 9.3.3.2.4. By End User
10. Middle East and Africa Synthetic Hormones Market Outlook
- 10.1. Market Size & Forecast
- 10.2. Market Share & Forecast
- 10.2.1. By Product
- 10.2.2. By Route of Administration
- 10.2.3. By Application
- 10.2.4. By End User
- 10.2.5. By Country
- 10.3. MEA: Country Analysis
- 10.3.1. South Africa Synthetic Hormones Market Outlook
- 10.3.1.1. Market Size & Forecast
- 10.3.1.2. Market Share & Forecast
- 10.3.1.2.1. By Product
- 10.3.1.2.2. By Route of Administration
- 10.3.1.2.3. By Application
- 10.3.1.2.4. By End User
- 10.3.2. Saudi Arabia Synthetic Hormones Market Outlook
- 10.3.2.1. Market Size & Forecast
- 10.3.2.2. Market Share & Forecast
- 10.3.2.2.1. By Product
- 10.3.2.2.2. By Route of Administration
- 10.3.2.2.3. By Application
- 10.3.2.2.4. By End User
- 10.3.3. UAE Synthetic Hormones Market Outlook
- 10.3.3.1. Market Size & Forecast
- 10.3.3.2. Market Share & Forecast
- 10.3.3.2.1. By Product
- 10.3.3.2.2. By Route of Administration
- 10.3.3.2.3. By Application
- 10.3.3.2.4. By End User
11. Market Dynamics
- 11.1. Drivers
- 11.2. Challenges
12. Market Trends & Developments
- 12.1. Recent Developments
- 12.2. Product Launches
- 12.3. Mergers & Acquisitions
13. Global Synthetic Hormones Market: SWOT Analysis
14. Competitive Landscape
- 14.1. Acerus Pharmaceuticals Corp.
- 14.1.1. Business Overview
- 14.1.2. Product & Service Offerings
- 14.1.3. Recent Developments
- 14.1.4. Financials (If Listed)
- 14.1.5. Key Personnel
- 14.1.6. SWOT Analysis
- 14.2. American Regent, Inc.
- 14.3. Anhui Anke Biotechnology (Group) Co. Ltd.
- 14.4. BioPartners, Inc
- 14.5. Eli Lilly and Company
- 14.6. Endo Pharmaceuticals, Inc.
- 14.7. F. Hoffmann-La Roche Ltd.
- 14.8. IBSA Institut Biochimique SA
- 14.9. Lupin Pharmaceuticals, Inc.
- 14.10.Pfizer, Inc
15. Strategic Recommendations
16. About Us & Disclaimer
